The World Health Organization-certified PyongSu Pharma joint venture (J/V) took “drastic measures” to keep operating in North Korea in order to avoid falling afoul of recent United Nations sanctions, Managing Director Remy Lardinois has told NK News.

A creative but risky solution now means that PyongSu Pharma will reportedly be able to continue operations in the DPRK despite a UN-mandated 120-day window for joint ventures to cease operations there passing on January 10.

“In order to avoid breaching UN sanctions, NDCP, the majority partner of PyongSu Pharma took drastic measures,” Managing Director Remy Lardinois said, referring to legislation obliging the